Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Date:3/11/2008

able, less current portion - 119,000

Capital lease obligation, less current portion 17,000 30,000

Deferred license revenue - 4,000

Commitments and contingencies

STOCKHOLDERS' EQUITY:

Preferred stock-$.001 par value;

authorized 5,000,000 shares; non-voting;

nil shares outstanding - -

Common stock-$.001 par value; authorized

325,000,000 shares; outstanding -

226,210,617 and 196,112,201, respectively 226,000 196,000

Additional paid-in capital 245,982,000 224,453,000

Accumulated deficit (224,677,000) (207,660,000)

Total stockholders' equity 21,531,000 16,989,000

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $28,241,000 $22,997,000

PEREGRINE PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

THREE MONTHS ENDED NINE MONTHS ENDED

January 31, January 31, January 31 January 31,

2008 2007 2008 2007

Unaudited Unaudited Unaudited Unaudited

REVENUES:

Contract

manufacturing

revenue $1,662,000 $347,000 $5,146,000 $1,381,000

License revenue 13,000 16,000 46,000 87,000

Total revenues 1,675,000 363,000 5,192,000 1,468,000

COSTS AND EXPENSES:

Cost of contract

manufacturing 1,289,000 223,000 3,872,000 1,247,000

Research and

development 4,941,000 3,907,000 13,665,000 11,868,000

Selling, general

and administrative 1,847,000 1,513,000 5,498,000 4,824,000

Total costs

and expenses
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
2. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
3. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
4. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
5. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
6. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
7. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
8. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
9. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
10. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
11. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 19, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or ... results of its Oral Amphotericin B (Oral Amp ... study, conducted by ImmuneCarta®, the immune monitoring business ... effectiveness of Oral Amp B in reactivating latent ... despite intensive treatment with antiretroviral therapy. ...
(Date:8/18/2014)... 18, 2014 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD), a ... and products for advanced microarray diagnostics, today announced it ... 22 at 2:00 pm ET.  During ... a brief review of SQI,s recent commercialization progress and ... industry veteran recently appointed to the Board of Directors ...
(Date:8/18/2014)... HIV Infection Drug Market and Pipeline Insight is a ... infection and the number of deaths due to AIDS has ... the globe. It has been estimated that the death rate ... with the rates for children being even much lower. A ... has been the improved access to antiretroviral drugs and therapy ...
(Date:8/18/2014)... Aug. 18, 2014 Dyadic International, Inc. ... patented and proprietary technologies are used to develop, ... the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme ... Registration Statement on Form 10 with the U.S. ... Logo - http://photos.prnewswire.com/prnh/20110621/CL06708LOGO ...
Breaking Biology Technology:iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 2SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4Dyadic International Files Form 10 Registration Statement 2Dyadic International Files Form 10 Registration Statement 3Dyadic International Files Form 10 Registration Statement 4
... , , , , ... Elbit Imaging,(NASDAQ: EMITF ) ("Elbit Imaging" "Company") announced ... - 60%, and Gamida,Cell - 28%; both on a fully diluted ... such subsidiary in a public offering on the,Tel Aviv Stock Exchange ...
... , LIVERPOOL, ... operations of Cambian healthcare Noel Tracey to lead ... Noel has more than 15 years, experience of ... private sector. In his previous role as,director of operations at ...
... DIEGO , Feb. 1 BioMed Realty Trust, Inc. (NYSE: ... fourth quarter and year ended December 31, 2009 after the ... Alan D. Gold , Chairman and Chief Executive Officer, and Kent ... call at 10:00 a.m. Pacific Time on Thursday, February ...
Cached Biology Technology:Elbit Imaging Evaluating Establishment of a Subsidiary to Hold its Bio-Tech and Medical Investments 2Elbit Imaging Evaluating Establishment of a Subsidiary to Hold its Bio-Tech and Medical Investments 3Elbit Imaging Evaluating Establishment of a Subsidiary to Hold its Bio-Tech and Medical Investments 4Elbit Imaging Evaluating Establishment of a Subsidiary to Hold its Bio-Tech and Medical Investments 5Noel Tracey to Head Up Gray Healthcare Recovery Team 2BioMed Realty Trust to Report 2009 Fourth Quarter and Year-End Results 2
(Date:8/19/2014)... abstinence syndrome (NAS) secondary to in-utero opioid exposure ... than others, but the underlying reasons are not ... are turned on or off) changes have recently ... University School of Medicine (BUSM) and Boston Medical ... study to identify some of these epigenetic changes ...
(Date:8/19/2014)... college biology and other science courses are increasingly ... and now they have a new textbook to ... Sciences," published this month by Princeton Press and ... Mathematical and Biological Synthesis (NIMBioS), teaches readers about ... used to explore and explain biological phenomena. , ...
(Date:8/19/2014)... UTSA researchers has been awarded a nearly $40,000 grant ... (NCPTT), an office of the National Park Service (NPS) ... fund a one-year study of the energy efficiency and ... in hot, humid climates. , Radiant barriers are reflective ... reflect heat back, thereby reducing the amount of heat ...
Breaking Biology News(10 mins):In-utero methadone, Subutex exposure could alter gene expression, cause severe Neonatal Abstience Syndrome 2New textbook introduces undergraduates to mathematics for the life sciences 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 3
... WORCESTER, Mass. Cranberry sauce is not the star ... comes to health benefits, the lowly condiment takes center ... have found that compounds in cranberries are able to ... host of human illnesses (from kidney infections to gastroenteritis ...
... successful wastewater fuel cell, researchers have coaxed common bacteria ... Bruce Logan and colleagues at Penn State University had ... Now, using starter material that could theoretically be sourced ... same microbes to generate hydrogen. By tweaking their ...
... gone" Thats the mystery The Academy of Natural Sciences ... will shed light on the environmental health of the ... less than two inches longonce were abundant in the ... steady decline has prompted Pennsylvania to classify the fish ...
Cached Biology News:Cranberry sauce: good for what ails you 2Cranberry sauce: good for what ails you 3Microbes churn out hydrogen at record rate 2Tiny fish can yield big clues to Delaware River health 2
... Cell Dissociation Buffers are membrane-filtered ... salts chelating agents and cell-conditioning agents ... balanced salt solution or Ca2+- ... dissociation of mammalian cells from support ...
Request Info...
Request Info...
...
Biology Products: